PE20030800A1 - Forma de dosificacion oral de liberacion controlada - Google Patents

Forma de dosificacion oral de liberacion controlada

Info

Publication number
PE20030800A1
PE20030800A1 PE2003000145A PE2003000145A PE20030800A1 PE 20030800 A1 PE20030800 A1 PE 20030800A1 PE 2003000145 A PE2003000145 A PE 2003000145A PE 2003000145 A PE2003000145 A PE 2003000145A PE 20030800 A1 PE20030800 A1 PE 20030800A1
Authority
PE
Peru
Prior art keywords
openings
dosage form
erosionable
solvate
erosion
Prior art date
Application number
PE2003000145A
Other languages
English (en)
Inventor
Vincenzo Re
Luigi Martini
Chi Leung Li
Helen Anne Willy
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203297A external-priority patent/GB0203297D0/en
Priority claimed from GBGB0203296.9A external-priority patent/GB0203296D0/en
Priority claimed from GB0203298A external-priority patent/GB0203298D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20030800A1 publication Critical patent/PE20030800A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

QUE COMPRENDE: a)UN NUCLEO EROSIONABLE, QUE ESTA COMPUESTO POR: i)UNA BASE DEBIL FARMACEUTICAMENTE ACTIVA O UNA SAL O SOLVATO DE LA MISMA: b)UN RECUBRIMIENTO EROSIONABLE EN TORNO A DICHO NUCLEO, CUYO ESPESOR ES DE 0,05 mm A 0,5 mm, QUE COMPRENDE UNA O MAS ABERTURAS QUE SE EXTIENDEN COMPLETAMENTE A TRAVES DE DICHO RECUBRIMIENTO, PERO QUE NO PENETRAN EN (a) Y QUE COMUNICAN EL MEDIO DE USO CON (a); DONDE, LA LIBERACION DE (i) A PARTIR DE LA FORMA DE DOSIFICACION OCURRE A TRAVES DE LAS ABERTURAS POR EROSION DE (a) Y A TRAVES DE LA EROSION DE (b) EN CONDICIONES DE pH MAYOR A 4,5. ASIMISMO, EL MATERIAL DE (b) ES SELECCIONADO DE: POLIMEROS DE POLIMETACRILATO, POLI(ACETATO-FTALATO DE VINILO) COPROCESADO, ACETATO-TRIMELITATO DE CELULOSA, ACETATO-FTALLATO DE CELULOSA, LACA, POLIMEROS DE FTALATO DE HIDROXIPROPILMETILCELULOSA Y SUS COPOLIMEROS, Y MEZCLAS DE ELLOS; EL NUCLEO ES PREDOMINANTEMENTE HIDROXIPROPILMETILCELULOSA Y LACTOSA; LA BASE DEBIL ES 5-[4-[2-(N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDIN-2,4-DIONA O UNA SAL O SOLVATO FARMACEUTICAMENTE ACEPTABLE DE LA MISMA; Y, EL TAMANO DE LAS ABERTURAS ESTAN EN EL INTERVALO DE 5 mm A 8 mm. SE REFIERE TAMBIEN AL PROCEDIMIENTO PARA PREPARAR DICHA FORMA DE DOSIFICACION
PE2003000145A 2002-02-12 2003-02-10 Forma de dosificacion oral de liberacion controlada PE20030800A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0203297A GB0203297D0 (en) 2002-02-12 2002-02-12 Novel composition
GBGB0203296.9A GB0203296D0 (en) 2002-02-12 2002-02-12 Novel composition
GB0203298A GB0203298D0 (en) 2002-02-12 2002-02-12 Novel composition

Publications (1)

Publication Number Publication Date
PE20030800A1 true PE20030800A1 (es) 2003-10-31

Family

ID=27738830

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000145A PE20030800A1 (es) 2002-02-12 2003-02-10 Forma de dosificacion oral de liberacion controlada

Country Status (34)

Country Link
EP (1) EP1474114B1 (es)
JP (2) JP2005526031A (es)
KR (2) KR101048925B1 (es)
CN (1) CN100444833C (es)
AP (1) AP1736A (es)
AR (1) AR038417A1 (es)
AT (1) ATE455540T1 (es)
AU (1) AU2003245763B2 (es)
BR (1) BRPI0307319B8 (es)
CA (1) CA2475544A1 (es)
CL (1) CL2007003010A1 (es)
CO (1) CO5601025A2 (es)
CY (1) CY1109939T1 (es)
DE (1) DE60331041D1 (es)
DK (1) DK1474114T3 (es)
EA (1) EA008286B1 (es)
EC (1) ECSP045232A (es)
ES (1) ES2336319T3 (es)
HK (1) HK1072194A1 (es)
IL (1) IL163098A (es)
IS (1) IS2747B (es)
MA (1) MA27689A1 (es)
MX (1) MXPA04007794A (es)
MY (1) MY139719A (es)
NO (1) NO334453B1 (es)
NZ (1) NZ534152A (es)
OA (1) OA12770A (es)
PE (1) PE20030800A1 (es)
PL (1) PL206596B1 (es)
PT (1) PT1474114E (es)
SI (1) SI1474114T1 (es)
TW (1) TWI286079B (es)
UY (1) UY27660A1 (es)
WO (1) WO2003068195A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0120835D0 (en) 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AR045330A1 (es) * 2003-08-07 2005-10-26 Sb Pharmco Inc Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP2363117B1 (en) * 2006-01-27 2015-08-19 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
RU2428176C2 (ru) * 2006-01-27 2011-09-10 Юранд, Инк. Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
SI1131070T1 (sl) * 1998-11-12 2008-12-31 Smithkline Beecham Plc Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes

Also Published As

Publication number Publication date
IS7383A (is) 2004-08-05
BRPI0307319B8 (pt) 2021-05-25
EP1474114B1 (en) 2010-01-20
ES2336319T3 (es) 2010-04-12
AU2003245763A1 (en) 2003-09-04
EA200401071A1 (ru) 2004-12-30
SI1474114T1 (sl) 2010-04-30
DE60331041D1 (de) 2010-03-11
JP2010159301A (ja) 2010-07-22
MXPA04007794A (es) 2004-10-15
DK1474114T3 (da) 2010-04-12
JP2005526031A (ja) 2005-09-02
NO334453B1 (no) 2014-03-03
ECSP045232A (es) 2004-09-28
AU2003245763B2 (en) 2008-12-11
HK1072194A1 (en) 2005-08-19
CL2007003010A1 (es) 2008-01-25
IS2747B (is) 2011-08-15
ATE455540T1 (de) 2010-02-15
CN1655768A (zh) 2005-08-17
AP2004003087A0 (en) 2004-09-30
PL206596B1 (pl) 2010-08-31
TW200307567A (en) 2003-12-16
WO2003068195A1 (en) 2003-08-21
KR101048925B1 (ko) 2011-07-12
BR0307319A (pt) 2005-01-04
CO5601025A2 (es) 2006-01-31
AR038417A1 (es) 2005-01-12
PL371368A1 (en) 2005-06-13
CA2475544A1 (en) 2003-08-21
EP1474114A1 (en) 2004-11-10
CN100444833C (zh) 2008-12-24
KR20100086084A (ko) 2010-07-29
AP1736A (en) 2007-05-02
EA008286B1 (ru) 2007-04-27
MY139719A (en) 2009-10-30
CY1109939T1 (el) 2014-09-10
NO20043633L (no) 2004-10-27
NZ534152A (en) 2006-11-30
MA27689A1 (fr) 2006-01-02
KR20040084900A (ko) 2004-10-06
OA12770A (en) 2006-07-04
IL163098A (en) 2009-05-04
JP5279757B2 (ja) 2013-09-04
UY27660A1 (es) 2003-09-30
PT1474114E (pt) 2010-03-04
BRPI0307319B1 (pt) 2018-05-02
TWI286079B (en) 2007-09-01

Similar Documents

Publication Publication Date Title
PE20030800A1 (es) Forma de dosificacion oral de liberacion controlada
ATE512659T1 (de) Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
NO992097L (no) Polymerholdig preparat med kontrollert avgivelse av aktiv forbindelse
PT1385489E (pt) Granulados revestidos tendo por base inibidores da enzima de conversao de angiotensina
ES2548878T3 (es) Métodos de tratamiento de úlceras de la piel
ID29125A (id) Mekanisme penopang bonggol dan aktuator piesoelektrik film tipis
BR9905923A (pt) Agente de liberação de elemento de transferência/transfusão e métodos do mesmo
SG130190A1 (en) Method and device for enhancing transdermal agent flux
DK1727551T3 (da) Farmaceutisk sammensætning omfattende et benzodiazepinderivat og en inhibitor af RSV-fusionsproteinet
DK2258346T3 (da) Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor
WO2002090245A3 (en) Methods of forming microstructure devices
BRPI0515776A (pt) auxiliares de retenção e drenagem
HRP20050557A2 (en) Method for improving the pharmacokinetics of a nnrti
EP2072043A3 (en) Mesalazine tablet
ITMI20021928A1 (it) Apparecchiatura per la finitura di una superficie ottica di
PT1355635E (pt) Novo revestimento de pelicula
ITTO991137A0 (it) Monomeri di reticolazione per fotoresist e procedimento per la prepara zione di polimeri fotoresist utilizzanti tali monomeri.
ITRM20020529A1 (it) Polimeri sterilizzanti, processo di loro preparazione ed uso.
CY1106226T1 (el) Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης
AU2003272770A1 (en) Method and aparatus for dry releasing lenses from an anterior mold half
TW200717515A (en) Method of manufacturing a stamper for replicating a high density relief structure
CY1105354T1 (el) Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο
ATE304736T1 (de) Mikro-elektromechanisches system und verfahren zu dessen herstellung
EA200300345A1 (ru) Гидрохлоридная соль 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika

Legal Events

Date Code Title Description
FG Grant, registration